dc.contributor.author |
Hacioglu, MB |
|
dc.contributor.author |
Kostek, O |
|
dc.contributor.author |
Karabulut, S |
|
dc.contributor.author |
Tastekin, D |
|
dc.contributor.author |
Goksu, SS |
|
dc.contributor.author |
Alandag, C |
|
dc.contributor.author |
Akagunduz, B |
|
dc.contributor.author |
Bilgetekin, I |
|
dc.contributor.author |
Caner, B |
|
dc.contributor.author |
Sahin, AB |
|
dc.contributor.author |
Yildiz, B |
|
dc.contributor.author |
Kose, F |
|
dc.contributor.author |
Kaplan, MA |
|
dc.contributor.author |
Gulmez, A |
|
dc.contributor.author |
Dogan, E |
|
dc.contributor.author |
Guven, DC |
|
dc.contributor.author |
Gurbuz, M |
|
dc.contributor.author |
Ergun, Y |
|
dc.contributor.author |
Karaagac, M |
|
dc.contributor.author |
Demiray, AG |
|
dc.contributor.author |
Turker, S |
|
dc.contributor.author |
Sakalar, T |
|
dc.contributor.author |
Ozkul, O |
|
dc.contributor.author |
Telli, TA |
|
dc.contributor.author |
Sahin, S |
|
dc.contributor.author |
Kilickap, S |
|
dc.contributor.author |
Bilici, A |
|
dc.contributor.author |
Erdogan, B |
|
dc.contributor.author |
Cicin, I |
|
dc.date.accessioned |
2022-10-11T13:13:27Z |
|
dc.date.available |
2022-10-11T13:13:27Z |
|
dc.date.issued |
2020 |
|
dc.identifier.uri |
http://hdl.handle.net/11616/75656 |
|
dc.description.abstract |
Purpose: After failure of the first-line sorafenib treatment in advanced or metastatic stage hepatocellular carcinoma (HCC), regorafenib is one of the newly-approved targeted agents. We aimed to evaluate the efficacy of regorafenib in patients with advanced HCC treated in the secondor third-line setting. |
|
dc.description.abstract |
Methods: In this retrospective and multicenter study, advanced HCC patients not eligible for local therapies, who received a secondor third-line regorafenib therapy after progression on the first-line sorafenib or sequential therapy with chemotherapy (CT) followed by sorafenib, were included. |
|
dc.description.abstract |
Results: In the first-line setting, 28 (28.9%) patients received CT and 69 (71.1%) patients received sorafenib. There were 24 (24.7%) patients who were intolerant to sorafenib. Disease control rate (DCR) was 53.6% for all patients treated with regorafenib, 62.3% in patients who received regorafenib in the second-line, and 32.1% for those receiving regorafenib in the third-line (p=0.007). Median progression-free survival (PFS) and overall survival (OS) were 5.6 (range; 4.3-6.9) and 8.8 (range, 6.3-11.3) months for all patients treated with regorafenib vs. 7.1 months and 10.3 months for patients who received regorafenib in the second-line vs. 5.1 and 8.7 months for patients who received regorafenib in the third-line, respectively; however, there was no statistically significant difference (p(PFS)=0.22 and p(OS)=0.85). |
|
dc.description.abstract |
Conclusion: Although receiving CT as a first-line therapy in advanced HCC patients did not affect the survival rates of subsequent regorafenib therapy, it might diminish the DCR of regorafenib. |
|
dc.source |
JOURNAL OF BUON |
|
dc.title |
Efficacy of regorafenib in the second-and third-line setting for |
|
dc.title |
patients with advanced hepatocellular carcinoma: A real life data of |
|
dc.title |
multicenter study from Turkey |
|